Spotlighting the U.S. companies bringing AI into medicine.
NVIDIA is scheduled to report its Q2 FY2027 earnings on August 26, 2026. High importance is estimated due to the company's significant market influence; analysts forecast EPS around $2.01-$2.09 and revenue guidance is approximately $91 billion forecasted. This event is scheduled.
Second quarter 2026 financial and operating results scheduled to be reported after market close on August 11, 2026, scheduled.
Q2 2026 financial results and conference call scheduled. This is a key event for investors to assess the company's growth trajectory and strategy in the health and wellness sector, scheduled.
Natera is scheduled to release its Q2 2026 financial results after the market closes on August 6, 2026. This is a recurring, significant event, and its importance is estimated as High based on substantial market reactions to past earnings reports scheduled.
Caris Life Sciences will report its second quarter 2026 financial results on August 5, 2026; medium importance estimated for standard earnings impact, scheduled.
Q2 2026 earnings release and conference call on August 5, 2026; low impact is estimated as the announcement is a routine scheduling event, scheduled.
Q2 2026 earnings release is expected after market close on August 5, 2026. This date is based on past reporting schedules and is not yet officially confirmed by the company. Low importance is estimated as the market typically waits for actual results expected
Q2 2026 earnings release scheduled; analysts forecast an EPS of -$2.34 to -$2.68. Neutral impact expected as the forecast aligns with market expectations.
Q2 2026 earnings release with analysts forecasting an EPS of approximately -$0.24; as earnings releases typically cause significant price volatility, a medium importance is expected.
AbbVie to announce second-quarter 2026 financial results before the market opens on 2026-07-31. High importance estimated due to potential for significant volatility following the report, scheduled.
Q2 2026 earnings results and conference call scheduled for 2026-07-30. Analysts forecast revenue of approximately $380 million and an EPS of -$0.15, which would be an improvement from -$0.22 year-over-year, making a significant market reaction likely expected.
H1 and Q2 2026 earnings results scheduled to be released. A low impact is estimated as this is a routine financial disclosure scheduled.
Alphabet is scheduled to release its second-quarter 2026 financial results after the market closes on July 22, 2026; analysts forecast focus on Google Cloud and AI growth, with high importance estimated.
Chief Accounting Officer Irene Becklund announced her departure, effective October 9, 2026, after more than seven years with the company. The CFO will assume her duties in the interim.
Q2 2026 earnings report on July 16, 2026, with $2.89B revenue and $2.80 EPS beating estimates, but lowered guidance led to a >12% price drop, expected.
NVIDIA announced a partnership with Japan's Noetra consortium on July 16, 2026, to build a national AI factory powered by 27,500 Rubin GPUs and 13,750 Vera CPUs.
Highlighted a landmark publication on the successful real-world deployment of the Paige Prostate AI Suite in the UK's National Health Service, showing enhanced diagnostic precision and faster turnaround times. Following the news, Guggenheim raised its price target on the stock.
Announced an exclusive license agreement with Dizal Pharmaceutical to acquire worldwide rights to Zegfrovy, an oral lung cancer therapy. The deal includes a $600 million upfront payment and up to $900 million in milestones.
Announced the offering of in-house PTEN immunohistochemistry (IHC) testing for metastatic prostate cancer on July 14, 2026; medium importance estimated for product line expansion, expected.